학술논문
Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3+T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation with Matched Unrelated Donor Peripheral Blood Stem Cells or Bone Marrow Grafts
Document Type
Article
Author
Lum, Su Han; James, Beki; Ottaviano, Giorgio; Ewins, Anna-Maria; Patrick, Katharine; Ali, Salah; Carpenter, Ben; Silva, Juliana; Tewari, Sanjay; Furness, Caroline; Thomas, Arun; Shenton, Geoff; Bonney, Denise; Moppett, John; Hambleton, Sophie; Gennery, Andrew R; Amrolia, Persis; Gibson, Brenda; Hough, Rachael; Rao, Kanchan; Slatter, Mary; Wynn, Robert
Source
Transplantation and Cellular Therapy; 20240101, Issue: Preprints
Subject
Language
ISSN
26666375; 26666367
Abstract
•Rates of severe aGVHD and cGVHD are comparable in PBSC transplantation and BM transplantation after alemtuzumab-based conditioning.•Alemtuzumab, dual GVHD prophylaxis, and CD3+T cell dose ≤5 × 108/kg are associated with reduced GVHD after PBSC transplantation.•We identified a potential strategy to optimize the use of PBSCs in children.